Xintela AB

Equities

XINT

SE0007756903

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 10:32:03 2024-04-26 am EDT			5-day change	1st Jan Change
0.281 ^SEK	+2.55%		+6.04%	+3.69%

Feb. 28	Xintela AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	CI
Feb. 20	Xintela Names New Chief Scientific Officer	MT

Targinta's CEO to BioStock: "Strong interest in ADCs in 2023"

January 22, 2024 at 04:11 am EST

During 2023, we have witnessed several significant business deals involving Antibody-drug conjugates (ADC), both in preclinical and clinical phase. This signals a continued strong interest in the field. AbbVie made a multi-billion dollar acquisition of ImmunoGen, Merck entered into a development agreement with Daiichi, and Pfizer acquired Seagen for a record amount. Evy Lundgren-Åkerlund, CEO of ADC developer Targinta, shares her analysis.

Read the full article at biostock.se:

https://www.biostock.se/en/2024/01/targintas-ceo-strong-interest-in-adcs-in-2023/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

https://news.cision.com/xintela-ab/r/targinta-s-ceo-to-biostock---strong-interest-in-adcs-in-2023-,c3913111

Latest news about Xintela AB

Xintela AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 28	CI
Xintela Names New Chief Scientific Officer	Feb. 20	MT
Xintela Appoints Lucienne Vonk as Chief Scientific Officer	Feb. 19	CI
Xintela AB Announces First Patient Dosed in It's Clinical Study on Difficult-To-Heal Leg Ulcers	Dec. 21	CI
Xintela Publishes Efficacy Results with EQSTEM from Preclinical Equine OA Study	Dec. 20	CI
Xintela AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 24	CI
Xintela's Stem Cell Product, Xstem, Assessed as Safe At All Dose Levels in Knee Osteoarthritis Clinical Study	23-10-13	CI
Xintela AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-30	CI
Xintela Receives Product Patent in USA for Chondrocyte-Based Products	23-08-15	CI
Xintela Completes XSTEM Dosing at Third and Final Dose Level in Knee Osteoarthritis Clinical Study	23-06-22	CI
Xintela AB Announces Clinical Study with XSTEM for Knee Oeoarthritis Makes Good Progress	23-06-01	CI
Xintela AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-25	CI
Xintela AB Initiates Last Dose Level in Knee Osteoarthritis Study	23-05-02	CI
Xintela Starts Last Dose Level of Xstem in Knee Osteoarthritis Clinical Study	23-04-13	CI
Xintela AB Completes Dosing of XSTEM Second Dose Level in Knee Osteoarthritis Clinical Study	23-03-03	CI
Xintela AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	23-02-24	CI
Xintela and Northx Biologics Sign Collaboration Framework Agreement	22-12-14	CI
Xintela AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-25	CI
Xintela AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-25	CI
Xintela Starts Next Dose Level of Xstem in Knee Osteoarthritis Clinical Study	22-11-09	CI
Xintela Completes Dosing of Xstem First Dose Level in Knee Osteoarthritis Clinical Study	22-09-30	CI
Xintela AB Appoints Peter Ekolind as Acting CEO, Effective October 1, 2022	22-09-22	CI
Xintela AB Starts Clinical Study with XSTEM for Difficult-To-Heal Leg Ulcers	22-09-20	CI
Xintela AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-26	CI
Xintela AB announced that it has received SEK 8.3 million in funding from Flerie Invest AB	22-08-02	CI

Chart Xintela AB

Duration

Period

More charts

Company Profile

Xintela AB (Xintela) is a Sweden-based biomedical company engaged in the fields of regenerative medicine and cancer, with particular focus on cartilage damage and brain tumors. In the field of regenerative medicine, the Company focuses on cartilage damage and osteoarthritis, and in the field of brain tumors, its focuses on the development of a treatment for glioblastoma, an aggressive tumor. The Company has developed therapeutic antibodies, which bind to cancer cells. It has also developed XINMARK, a marker technology which consists of specific proteins, which work as recognition flags on the surface of certain cells. The markers make it possible to identify and select certain types of stem cells which can develop into cartilage cells.

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
XINTELA AB	+3.69%	14.53M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+49.22%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research